| Literature DB >> 30886064 |
Shanshan Liu1, Weiqin Chang2, Yuemei Jin1, Chunyang Feng1, Shuying Wu1, Jiaxing He1, Tianmin Xu3.
Abstract
Cervical cancer is the fourth most common female cancer in the world. It is well known that cervical cancer is closely related to high-risk human papillomavirus (HPV) infection. However, epigenetics has increasingly been recognized for its role in tumorigenesis. Epigenetics refers to changes in gene expression levels based on non-gene sequence changes, primarily through transcription or translation of genes regulation, thus affecting its function and characteristics. Typical post-translational modifications (PTMs) include acetylation, propionylation, butyrylation, malonylation and succinylation, among which the acetylation modification of lysine sites has been studied more clearly so far. The acetylation modification of lysine residues in proteins is involved in many aspects of cellular life activities, including carbon metabolism, transcriptional regulation, amino acid metabolism and so on. In this review, we summarize the latest discoveries on cervical cancer development arising from the aspect of acetylation, especially histone acetylation.Entities:
Keywords: Cervical cancer; Epigenetics; Histone acetylation
Year: 2019 PMID: 30886064 PMCID: PMC6465204 DOI: 10.1042/BSR20190527
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Figure 1Histone acetylation and deacetylation
Summary of HDACIs in cervical cancer recently
| Name | Type | Property | Disease or cell | Reference |
|---|---|---|---|---|
| 2-Aminobenzamides compound M122 | Especially inhibit HDAC1 HDAC2 | High potency and selectivity | HeLa, etc. | [ |
| 2-Oxo-1,3-thiazolidine derivatives | Class II HDACIs | Good bioactivities, oral bioavailability | Cervical cancer | [ |
| TSA | Except for class III HDACs | Acetylated HIF-1α at lysine 674 | HeLa cells | [ |
| Vorinostat (SAHA) | Pan-HDAC inhibitor | Reduce E6 and E7 activity | HPV infections | [ |
| Oxamflatin | HDAC inhibitor | Induces E-cadherin Expression | HeLa cells | [ |
| Valproic acid (VPA) | HDAC inhibitor | Re-expression of E-cadherin | HeLa and TC1 cell lines | [ |
| OH-VPA | HDAC inhibitor | Antioxidant | HeLa cells | [ |
| Genistein | HDAC families | Time-dependent | HeLa cells | [ |
| Caffeic acid | HDAC inhibitor | Induction of apoptosis | Colon and cervical cancer cells | [ |
| Mocetinostat and entinostat | Class I HDACIs | Pan-gynecologic cancer inhibitors | Ovarian, cervical cells, etc. | [ |
| Scriptaid (SCR) | HDAC-8 inhibitor | Inhibit HDAC-8 effectively than TSA | HeLa cells, etc. | [ |
| Isatin-based compounds | HDACIs | Inhibit proliferation | HeLa cells | [ |